Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT), a global leader in analytical instrumentation and laboratory technologies, provides critical solutions for pharmaceutical development, food safety testing, and environmental monitoring. This dedicated news hub aggregates official announcements, financial disclosures, and strategic updates directly impacting the company's market position and technological advancements.
Investors and industry professionals will find curated updates including quarterly earnings reports, product innovation announcements, executive leadership changes, and regulatory developments. Our repository ensures timely access to filings, partnership agreements, and scientific breakthroughs related to Waters' chromatography systems, mass spectrometry platforms, and thermal analysis instruments.
Key content categories include financial performance updates, new product launches, research collaborations, and operational expansions. Bookmark this page to monitor developments affecting Waters' role in life sciences R&D, quality assurance protocols, and laboratory informatics solutions across 100+ countries.
Waters Corporation (NYSE:WAT) has launched the BioAccord System with ACQUITY Premier, a new LC-MS system aimed at enhancing multi-attribute monitoring of biotherapeutics. This system significantly improves analyte recovery and assay reproducibility, addressing challenges posed by analyte-to-metal interactions. Expected to facilitate quicker access to mass spectrometry data, the system aims to lower costs and expedite the delivery of medicines to patients. Customer shipments are set to commence at the month’s end.
Waters Corporation (NYSE:WAT) has launched the BioAccord System with ACQUITY Premier, an advanced LC-MS system designed for improved monitoring of biotherapeutics. This system significantly enhances analyte recovery and assay reproducibility, allowing faster access to critical data about biologics. Key features include MaxPeak HPS technology, which eliminates analyte-to-metal interactions, resulting in up to 300% increase in sensitivity for glycan profiling. Shipments are expected to begin soon, which may help accelerate the delivery of essential medicines to patients.
Waters Corporation (NYSE:WAT) announced that its CEO, Udit Batra, will present at the Bank of America Global Healthcare Conference on September 16, 2021, at 3:55 PM BST (10:55 AM Eastern Time). Investors can access the live webcast on Waters' investor relations website. Waters, a leader in specialty measurement, has over 7,400 employees and operates in 35 countries, with products available in more than 100 countries.
Waters Corporation (NYSE:WAT) announced that its CEO, Udit Batra, will engage in a virtual fireside chat at Morgan Stanley’s 19th Annual Global Healthcare event on September 14th, 2021, at 8:45 AM EST. Investors can access the live webcast through Waters’ investor relations website. Waters has been a leader in chromatography and mass spectrometry for over 60 years, with more than 7,400 employees across 35 countries.
Waters Corporation reported a strong second quarter 2021 with sales reaching $682 million, a 31% increase from $520 million a year prior, driven by a 4% boost from foreign currency translation. GAAP diluted EPS rose to $2.69 from $1.98 in Q2 2020. For the first half of 2021, sales grew to $1,290 million, with 31% growth compared to the same period last year. The company anticipates full-year sales growth between 13% to 15% and expects non-GAAP EPS of $10.50 to $10.70.
Waters Corporation (NYSE:WAT) will host a live webcast for its Q2 2021 financial results on August 3, 2021, at 8:00 a.m. ET. Investors can access the call through Waters' official website. The replay will be available until August 10, 2021. Waters is a leader in specialty measurement, focusing on chromatography, mass spectrometry, and thermal analysis for life, materials, and food sciences. With over 7,400 employees and operations in 35 countries, Waters has a significant global presence.
Waters Corporation (NYSE:WAT) has launched the TRIOS AutoPilot software, enhancing its thermal analyzer product line under the TA Instruments Division. This software allows laboratory staff to develop standard operating procedures (SOPs) up to 25% faster and eliminates transcription errors, improving productivity and consistency in thermal analysis. It utilizes Google’s Blockly interface, making it user-friendly for script creation without advanced programming skills. The TRIOS AutoPilot includes built-in compliance features, ensuring regulatory adherence, and is available globally.
Waters Corporation (NYSE:WAT) has expanded its collaboration with Singapore's Bioprocessing Technology Institute (BTI) to enhance analytics in glycomics and metabolomics. The partnership aims to improve the rapid identification of complex biomolecules that are crucial for biologics manufacturing. Utilizing advanced instruments like the SYNAPT™ mass spectrometry system, the project addresses the challenges of characterizing biopharmaceuticals through data analytics and machine learning. This collaboration builds on a successful relationship since 2014, targeting cost reduction and efficiency in biomanufacturing processes.
Waters Corporation (NYSE: WAT) has appointed Wei Jiang to its Board of Directors, effective July 14, 2021. Wei currently serves as Executive Vice President at Bayer Pharmaceuticals for the China and APAC regions. His expertise in driving results in fast-growing markets, particularly in China, is viewed as a significant asset for Waters. Dr. Udit Batra, CEO, notes that Wei's experience aligns with the company's growth strategy in the pharmaceutical sector. Wei expressed enthusiasm about contributing to Waters' ongoing transformation, highlighting growth potential in China's pharma market.
Waters Corporation (NYSE:WAT) has launched the Waters Arc Premier System, the first liquid chromatography system designed for 2.5 – 3.5 micron columns featuring MaxPeak High Performance Surface (HPS) technology. This system reduces analyte-surface interactions, thereby improving analytical results for laboratories. Benefits include increased sensitivity, reproducibility, and potential savings of 2-3 days per assay by eliminating passivation. The combination of the Arc Premier System and MaxPeak Premier Columns aims to enhance productivity, accuracy, and confidence in pharmaceutical analysis.